{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T05:03:21Z","timestamp":1789707801289,"version":"4.0.1"},"reference-count":101,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,12,22]],"date-time":"2020-12-22T00:00:00Z","timestamp":1608595200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100010109","name":"Medizinische Universit\u00e4t Graz","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100010109","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Paediatric Respiratory Reviews"],"published-print":{"date-parts":[[2022,6]]},"DOI":"10.1016\/j.prrv.2020.12.001","type":"journal-article","created":{"date-parts":[[2020,12,24]],"date-time":"2020-12-24T17:18:38Z","timestamp":1608830318000},"page":"9-16","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"special_numbering":"C","title":["Changing paradigms in the treatment of gastrointestinal complications of cystic fibrosis in the era of cystic fibrosis transmembrane conductance regulator modulators"],"prefix":"10.1016","volume":"42","author":[{"given":"Julia","family":"Konrad","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7628-030X","authenticated-orcid":false,"given":"Ernst","family":"Eber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5508-8271","authenticated-orcid":false,"given":"Vanessa","family":"Stadlbauer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"8","key":"10.1016\/j.prrv.2020.12.001_b0005","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1136\/gut.2004.062786","article-title":"Patterns of GI disease in adulthood associated with mutations in the CFTR gene","volume":"56","author":"Wilschanski","year":"2007","journal-title":"Gut"},{"issue":"6","key":"10.1016\/j.prrv.2020.12.001_b0010","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1097\/MCP.0000000000000520","article-title":"Cystic fibrosis survival: the changing epidemiology","volume":"24","author":"Corriveau","year":"2018","journal-title":"Curr Opin Pulm Med"},{"issue":"10059","key":"10.1016\/j.prrv.2020.12.001_b0015","doi-asserted-by":"crossref","first-page":"2519","DOI":"10.1016\/S0140-6736(16)00576-6","article-title":"Cystic fibrosis","volume":"388","author":"Elborn","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.prrv.2020.12.001_b0020","article-title":"CFTR modulator therapies \u2013 Effect on life expectancy in people with cystic fibrosis","author":"Balfour-Lynn","year":"2020","journal-title":"Paediatr Respir Rev"},{"issue":"155","key":"10.1016\/j.prrv.2020.12.001_b0025","doi-asserted-by":"crossref","first-page":"190112","DOI":"10.1183\/16000617.0112-2019","article-title":"Impact of CFTR modulator use on outcomes in people with severe cystic fibrosis lung disease","volume":"29","author":"Shteinberg","year":"2020","journal-title":"Eur Respir Rev"},{"key":"10.1016\/j.prrv.2020.12.001_b0030","doi-asserted-by":"crossref","first-page":"S2","DOI":"10.1016\/j.jcf.2017.07.007","article-title":"Cystic Fibrosis and gastroesophageal reflux disease","volume":"16","author":"Maqbool","year":"2017","journal-title":"J Cyst Fibros"},{"issue":"3","key":"10.1016\/j.prrv.2020.12.001_b0035","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1007\/s11894-012-0261-9","article-title":"Gastroesophageal reflux in cystic fibrosis: current understandings of mechanisms and management","volume":"14","author":"Mousa","year":"2012","journal-title":"Curr Gastroenterol Rep"},{"issue":"1","key":"10.1016\/j.prrv.2020.12.001_b0040","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.jcf.2012.09.002","article-title":"Eosinophilic esophagitis in cystic fibrosis: a case series and review of the literature","volume":"12","author":"Goralski","year":"2013","journal-title":"J Cyst Fibros"},{"issue":"7","key":"10.1016\/j.prrv.2020.12.001_b0045","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1111\/jgh.12546","article-title":"Cystic fibrosis: An update for clinicians. Part 1: Nutrition and gastrointestinal complications","volume":"29","author":"Haller","year":"2014","journal-title":"J Gastroenterol Hepatol"},{"issue":"5","key":"10.1016\/j.prrv.2020.12.001_b0050","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1097\/MPG.0000000000001131","article-title":"Morphological and functional assessment of oesophageal mucosa integrity in children with cystic fibrosis","volume":"62","author":"Brecelj","year":"2016","journal-title":"J Pediatr Gastroenterol Nutr"},{"issue":"1","key":"10.1016\/j.prrv.2020.12.001_b0055","doi-asserted-by":"crossref","DOI":"10.1186\/1471-2431-4-19","article-title":"High-dose ibuprofen therapy associated with esophageal ulceration after pneumonectomy in a patient with cystic fibrosis: a case report","volume":"4","author":"Mackey","year":"2004","journal-title":"BMC Pediatr"},{"issue":"5","key":"10.1016\/j.prrv.2020.12.001_b0060","doi-asserted-by":"crossref","first-page":"288","DOI":"10.14740\/gr917w","article-title":"Proton pump inhibitor use is associated with an increased frequency of hospitalization in patients with cystic fibrosis","volume":"10","author":"Ayoub","year":"2017","journal-title":"Gastroenterol Res"},{"issue":"1","key":"10.1016\/j.prrv.2020.12.001_b0065","doi-asserted-by":"crossref","DOI":"10.1186\/1471-2466-14-21","article-title":"Effect of esomeprazole versus placebo on pulmonary exacerbations in cystic fibrosis","volume":"14","author":"DiMango","year":"2014","journal-title":"BMC Pulm Med"},{"issue":"7","key":"10.1016\/j.prrv.2020.12.001_b0070","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1002\/phar.2125","article-title":"Use and incidence of adverse effects of proton pump inhibitors in patients with cystic fibrosis","volume":"38","author":"McCrory","year":"2018","journal-title":"Pharmacotherapy"},{"issue":"8","key":"10.1016\/j.prrv.2020.12.001_b0075","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1016\/j.jpedsurg.2007.03.030","article-title":"Outcomes of fundoplication in children with cystic fibrosis","volume":"42","author":"Boesch","year":"2007","journal-title":"J Pediatr Surg"},{"issue":"1","key":"10.1016\/j.prrv.2020.12.001_b0080","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1745-9974-5-1","article-title":"Cough in adult cystic fibrosis: diagnosis and response to fundoplication","volume":"5","author":"Fathi","year":"2009","journal-title":"Cough"},{"issue":"12","key":"10.1016\/j.prrv.2020.12.001_b0085","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1002\/ppul.22697","article-title":"The role of endoscopy and biopsy in the management of severe gastrointestinal disease in cystic fibrosis patients","volume":"48","author":"Shah","year":"2013","journal-title":"Pediatr Pulmonol."},{"issue":"1","key":"10.1016\/j.prrv.2020.12.001_b0090","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.jcf.2016.07.004","article-title":"Ivacaftor and symptoms of extra-oesophageal reflux in patients with cystic fibrosis and G551D mutation","volume":"16","author":"Zeybel","year":"2017","journal-title":"J Cyst Fibros"},{"issue":"2","key":"10.1016\/j.prrv.2020.12.001_b0095","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1002\/path.4634","article-title":"Pancreatic pathophysiology in cystic fibrosis","volume":"238","author":"Gibson-Corley","year":"2016","journal-title":"J Pathol"},{"issue":"1","key":"10.1016\/j.prrv.2020.12.001_b0100","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1097\/MPA.0000000000000963","article-title":"Pancreatic insufficiency in cystic fibrosis: influence of inflammatory response genes","volume":"47","author":"Marson","year":"2018","journal-title":"Pancreas"},{"issue":"8","key":"10.1016\/j.prrv.2020.12.001_b0105","doi-asserted-by":"crossref","DOI":"10.1016\/j.cgh.2018.01.027","article-title":"Diagnostic performance of measurement of fecal elastase-1 in detection of exocrine pancreatic insufficiency: systematic review and meta-analysis","volume":"16","author":"Vanga","year":"2018","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"3","key":"10.1016\/j.prrv.2020.12.001_b0110","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1016\/j.clnu.2016.03.004","article-title":"ESPEN-ESPGHAN-ECFS guidelines on nutrition care for infants, children, and adults with cystic fibrosis","volume":"35","author":"Turck","year":"2016","journal-title":"Clin Nutr"},{"issue":"3","key":"10.1016\/j.prrv.2020.12.001_b0115","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.anpedi.2018.05.022","article-title":"Real-world effectiveness of ivacaftor in children with cystic fibrosis and the G551D mutation","volume":"90","author":"Gomez-Pastrana","year":"2019","journal-title":"An Pediatr (Barc)"},{"issue":"11","key":"10.1016\/j.prrv.2020.12.001_b0120","doi-asserted-by":"crossref","first-page":"1654","DOI":"10.1002\/ppul.24454","article-title":"Pancreatic insufficiency converted to pancreatic sufficiency with ivacaftor","volume":"54","author":"Hamilton","year":"2019","journal-title":"Pediatr Pulmonol"},{"issue":"8","key":"10.1016\/j.prrv.2020.12.001_b0125","doi-asserted-by":"crossref","first-page":"E16","DOI":"10.1002\/ppul.24353","article-title":"Time for a gut check: pancreatic sufficiency resulting from CFTR modulator use","volume":"54","author":"Megalaa","year":"2019","journal-title":"Pediatr Pulmonol"},{"issue":"4","key":"10.1016\/j.prrv.2020.12.001_b0130","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/S2213-2600(18)30460-0","article-title":"Safety, pharmacokinetics, and pharmacodynamics of lumacaftor and ivacaftor combination therapy in children aged 2\u20135 years with cystic fibrosis homozygous for F508del-CFTR: an open-label phase 3 study","volume":"7","author":"McNamara","year":"2019","journal-title":"Lancet Respir Med"},{"issue":"6","key":"10.1016\/j.prrv.2020.12.001_b0135","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1016\/j.jcf.2019.03.009","article-title":"An open-label extension study of ivacaftor in children with CF and a CFTR gating mutation initiating treatment at age 2\u20135years (KLIMB)","volume":"18","author":"Rosenfeld","year":"2019","journal-title":"J Cyst Fibros"},{"issue":"7","key":"10.1016\/j.prrv.2020.12.001_b0140","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/S2213-2600(18)30202-9","article-title":"Ivacaftor treatment of cystic fibrosis in children aged 12 to <24 months and with a CFTR gating mutation (ARRIVAL): a phase 3 single-arm study","volume":"6","author":"Rosenfeld","year":"2018","journal-title":"Lancet Respir Med"},{"issue":"2","key":"10.1016\/j.prrv.2020.12.001_b0145","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/S2213-2600(15)00545-7","article-title":"Safety, pharmacokinetics, and pharmacodynamics of ivacaftor in patients aged 2\u20135 years with cystic fibrosis and a CFTR gating mutation (KIWI): an open-label, single-arm study","volume":"4","author":"Davies","year":"2016","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.prrv.2020.12.001_b0150","first-page":"99","article-title":"Restoration of exocrine pancreatic function in older children with cystic fibrosis on ivacaftor","volume":"35","author":"Nichols","year":"2020","journal-title":"Paediatr Respir Rev"},{"key":"10.1016\/j.prrv.2020.12.001_b0155","doi-asserted-by":"crossref","first-page":"S79","DOI":"10.1016\/j.jcf.2017.07.004","article-title":"Pancreatitis and pancreatic cystosis in cystic fibrosis","volume":"16","author":"Freeman","year":"2017","journal-title":"J Cyst Fibros"},{"issue":"8","key":"10.1016\/j.prrv.2020.12.001_b0160","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1016\/j.pan.2019.09.014","article-title":"Cystic fibrosis transmembrane conductance regulator modulators reduce the risk of recurrent acute pancreatitis among adult patients with pancreas sufficient cystic fibrosis","volume":"19","author":"Akshintala","year":"2019","journal-title":"Pancreatology"},{"issue":"3","key":"10.1016\/j.prrv.2020.12.001_b0165","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1097\/MPG.0000000000001788","article-title":"Reduction of recurrence risk of pancreatitis in cystic fibrosis with ivacaftor: case series","volume":"66","author":"Carrion","year":"2018","journal-title":"J Pediatr Gastroenterol Nutr"},{"issue":"6","key":"10.1016\/j.prrv.2020.12.001_b0170","doi-asserted-by":"crossref","first-page":"1857","DOI":"10.1016\/0016-5085(93)91085-V","article-title":"Localization of the cystic fibrosis transmembrane conductance regulator in human bile duct epithelial cells","volume":"105","author":"Cohn","year":"1993","journal-title":"Gastroenterology"},{"issue":"3","key":"10.1016\/j.prrv.2020.12.001_b0175","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1007\/s11894-004-0013-6","article-title":"Hepatobiliary complications of cystic fibrosis","volume":"6","author":"Feranchak","year":"2004","journal-title":"Curr Gastroenterol Rep"},{"issue":"2","key":"10.1016\/j.prrv.2020.12.001_b0180","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1097\/MOG.0000000000000508","article-title":"Modifier genes in cystic fibrosis-related liver disease","volume":"35","author":"Debray","year":"2019","journal-title":"Curr Opin Gastroenterol"},{"key":"10.1016\/j.prrv.2020.12.001_b0185","doi-asserted-by":"crossref","first-page":"S50","DOI":"10.1016\/j.jcf.2017.07.002","article-title":"Cystic fibrosis-related cirrhosis","volume":"16","author":"Leung","year":"2017","journal-title":"J Cyst Fibros"},{"issue":"4","key":"10.1016\/j.prrv.2020.12.001_b0190","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1016\/j.jcf.2020.05.002","article-title":"A longitudinal assessment of non-invasive biomarkers to diagnose and predict cystic fibrosis-associated liver disease","volume":"19","author":"Karnsakul","year":"2020","journal-title":"J Cyst Fibros"},{"issue":"12","key":"10.1016\/j.prrv.2020.12.001_b0195","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1080\/00365521.2018.1534986","article-title":"Evaluation of noninvasive markers for the diagnosis of cystic fibrosis liver disease","volume":"53","author":"Alexopoulou","year":"2018","journal-title":"Scand J Gastroenterol"},{"issue":"8","key":"10.1016\/j.prrv.2020.12.001_b0200","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1016\/j.cgh.2016.03.041","article-title":"Features of severe liver disease with portal hypertension in patients with cystic fibrosis","volume":"14","author":"Stonebraker","year":"2016","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"5","key":"10.1016\/j.prrv.2020.12.001_b0205","doi-asserted-by":"crossref","first-page":"1576","DOI":"10.1002\/hep.28016","article-title":"Aspartate aminotransferase to platelet ratio and fibrosis-4 as biomarkers in biopsy-validated pediatric cystic fibrosis liver disease","volume":"62","author":"Leung","year":"2015","journal-title":"Hepatology"},{"issue":"2","key":"10.1016\/j.prrv.2020.12.001_b0210","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1093\/jcag\/gwy029","article-title":"Transient elastography in the evaluation of cystic fibrosis-associated liver disease: systematic review and meta-analysis","volume":"2","author":"Lam","year":"2019","journal-title":"J Can Assoc Gastroenterol."},{"key":"10.1016\/j.prrv.2020.12.001_b0215","doi-asserted-by":"crossref","first-page":"S29","DOI":"10.1016\/S1569-1993(11)60006-4","article-title":"Best practice guidance for the diagnosis and management of cystic fibrosis-associated liver disease","volume":"10","author":"Debray","year":"2011","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.prrv.2020.12.001_b0220","article-title":"Interventions for preventing and managing advanced liver disease in cystic fibrosis","volume":"8","author":"Palaniappan","year":"2017","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.prrv.2020.12.001_b0225","article-title":"Ursodeoxycholic acid for cystic fibrosis-related liver disease","volume":"9","author":"Cheng","year":"2017","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.prrv.2020.12.001_b0230","unstructured":"Cystic Fibrosis Agents. LiverTox: clinical and research information on drug-induced liver injury. Bethesda (MD) 2012."},{"key":"10.1016\/j.prrv.2020.12.001_b0235","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.2147\/TCRM.S147164","article-title":"Triplet CFTR modulators: future prospects for treatment of cystic fibrosis","volume":"14","author":"Chaudary","year":"2018","journal-title":"Ther Clin Risk Manage"},{"key":"10.1016\/j.prrv.2020.12.001_b0240","article-title":"Biliary disease and cholecystectomy after initiation of elexacaftor\/ivacaftor\/tezacaftor in adults with cystic fibrosis","author":"Safirstein","year":"2020","journal-title":"J Cyst Fibros"},{"issue":"12","key":"10.1016\/j.prrv.2020.12.001_b0245","doi-asserted-by":"crossref","first-page":"761","DOI":"10.4254\/wjh.v11.i12.761","article-title":"Lumacaftor\/ivacaftor therapy is associated with reduced hepatic steatosis in cystic fibrosis patients","volume":"11","author":"Kutney","year":"2019","journal-title":"World J Hepatol"},{"issue":"5","key":"10.1016\/j.prrv.2020.12.001_b0250","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1097\/MPG.0000000000000765","article-title":"Improvement of hepatic steatosis in cystic fibrosis with ivacaftor therapy","volume":"60","author":"Hayes","year":"2015","journal-title":"J Pediatr Gastroenterol Nutr"},{"issue":"2","key":"10.1016\/j.prrv.2020.12.001_b0255","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1016\/j.jcf.2018.09.001","article-title":"IVACAFTOR restores FGF19 regulated bile acid homeostasis in cystic fibrosis patients with an S1251N or a G551D gating mutation","volume":"18","author":"van de Peppel","year":"2019","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.prrv.2020.12.001_b0260","doi-asserted-by":"crossref","first-page":"S32","DOI":"10.1016\/j.jcf.2017.06.007","article-title":"Meconium ileus in cystic fibrosis","volume":"16","author":"Sathe","year":"2017","journal-title":"J Cyst Fibros"},{"issue":"3","key":"10.1016\/j.prrv.2020.12.001_b0265","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1097\/MCP.0000000000000479","article-title":"Disease-modifying genetic factors in cystic fibrosis","volume":"24","author":"Marson","year":"2018","journal-title":"Curr Opin Pulm Med"},{"issue":"8","key":"10.1016\/j.prrv.2020.12.001_b0270","doi-asserted-by":"crossref","first-page":"1504","DOI":"10.1016\/j.jpedsurg.2017.11.040","article-title":"Long-term intestinal obstruction sequelae and growth in children with cystic fibrosis operated for meconium ileus: expectancies and surprises","volume":"53","author":"Mentessidou","year":"2018","journal-title":"J Pediatr Surg"},{"issue":"1","key":"10.1016\/j.prrv.2020.12.001_b0275","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1097\/MPG.0b013e3181a6e01d","article-title":"Defining DIOS and constipation in cystic fibrosis with a multicentre study on the incidence, characteristics, and treatment of DIOS","volume":"50","author":"Houwen","year":"2010","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"10.1016\/j.prrv.2020.12.001_b0280","article-title":"Interventions for preventing distal intestinal obstruction syndrome (DIOS) in cystic fibrosis","volume":"6","author":"Green","year":"2018","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.prrv.2020.12.001_b0285","first-page":"68","article-title":"Question 8: How should distal intestinal obstruction syndrome [DIOS]. be managed?","volume":"21","author":"Groves","year":"2017","journal-title":"Paediatr Respir Rev"},{"key":"10.1016\/j.prrv.2020.12.001_b0290","article-title":"Interventions for treating distal intestinal obstruction syndrome (DIOS) in cystic fibrosis","volume":"8","author":"Green","year":"2018","journal-title":"Cochrane Database Syst Rev"},{"issue":"4","key":"10.1016\/j.prrv.2020.12.001_b0295","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1016\/j.jcf.2016.02.002","article-title":"International prospective study of distal intestinal obstruction syndrome in cystic fibrosis: Associated factors and outcome","volume":"15","author":"Munck","year":"2016","journal-title":"J Cyst Fibros"},{"issue":"5","key":"10.1016\/j.prrv.2020.12.001_b0300","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1016\/j.jcf.2019.06.009","article-title":"A phase 3 study of tezacaftor in combination with ivacaftor in children aged 6 through 11years with cystic fibrosis","volume":"18","author":"Walker","year":"2019","journal-title":"J Cyst Fibros"},{"issue":"18","key":"10.1016\/j.prrv.2020.12.001_b0305","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1056\/NEJM199705013361803","article-title":"High-dose pancreatic-enzyme supplements and fibrosing colonopathy in children with cystic fibrosis","volume":"336","author":"FitzSimmons","year":"1997","journal-title":"N Engl J Med"},{"issue":"8889","key":"10.1016\/j.prrv.2020.12.001_b0310","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/S0140-6736(94)90817-6","article-title":"Strictures of ascending colon in cystic fibrosis and high-strength pancreatic enzymes","volume":"343","author":"Smyth","year":"1994","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.prrv.2020.12.001_b0315","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1007\/s100249900009","article-title":"Cystic fibrosis with fibrosing colonopathy in the absence of pancreatic enzymes","volume":"1","author":"Waters","year":"1998","journal-title":"Pediatr Dev Pathol"},{"issue":"9","key":"10.1016\/j.prrv.2020.12.001_b0320","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1097\/01.SMJ.0000129939.14179.FE","article-title":"Fibrosing colonopathy in an adult cystic fibrosis patient after discontinuing pancreatic enzyme therapy","volume":"97","author":"Mack","year":"2004","journal-title":"South Med J"},{"issue":"3","key":"10.1016\/j.prrv.2020.12.001_b0325","first-page":"356","article-title":"Fibrosing colonopathy revealing cystic fibrosis in a neonate before any pancreatic enzyme supplementation","volume":"35","author":"Serban","year":"2002","journal-title":"J Pediatr Gastroenterol Nutr"},{"issue":"3","key":"10.1016\/j.prrv.2020.12.001_b0330","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1136\/adc.66.3.307","article-title":"Appendicitis in cystic fibrosis","volume":"66","author":"Shields","year":"1991","journal-title":"Arch Dis Child"},{"issue":"3","key":"10.1016\/j.prrv.2020.12.001_b0335","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1007\/s00247-005-0049-2","article-title":"Abdominal manifestations of cystic fibrosis in children","volume":"36","author":"Chaudry","year":"2006","journal-title":"Pediatr Radiol"},{"issue":"3","key":"10.1016\/j.prrv.2020.12.001_b0340","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1148\/rg.263055101","article-title":"Review of the abdominal manifestations of cystic fibrosis in the adult patient","volume":"26","author":"Robertson","year":"2006","journal-title":"Radiographics"},{"issue":"9","key":"10.1016\/j.prrv.2020.12.001_b0345","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1155\/2001\/745361","article-title":"Colonic disorders in adult cystic fibrosis","volume":"15","author":"Chaun","year":"2001","journal-title":"Can J Gastroenterol"},{"issue":"3","key":"10.1016\/j.prrv.2020.12.001_b0350","first-page":"338","article-title":"The cause of rectal prolapse in children","volume":"142","author":"Zempsky","year":"1988","journal-title":"Am J Dis Child"},{"key":"10.1016\/j.prrv.2020.12.001_b0355","doi-asserted-by":"crossref","first-page":"301","DOI":"10.3389\/fmicb.2020.00301","article-title":"The cross-talk between gut microbiota and lungs in common lung diseases","volume":"11","author":"Zhang","year":"2020","journal-title":"Front Microbiol"},{"key":"10.1016\/j.prrv.2020.12.001_b0360","doi-asserted-by":"crossref","first-page":"2147","DOI":"10.3389\/fmicb.2018.02147","article-title":"Diet, microbiota and gut-lung connection","volume":"9","author":"Anand","year":"2018","journal-title":"Front Microbiol"},{"issue":"1","key":"10.1016\/j.prrv.2020.12.001_b0365","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-019-55028-7","article-title":"Gut microbiota in children with cystic fibrosis: a taxonomic and functional dysbiosis","volume":"9","author":"Coffey","year":"2019","journal-title":"Sci Rep"},{"key":"10.1016\/j.prrv.2020.12.001_b0370","doi-asserted-by":"crossref","unstructured":"de Freitas MB, Moreira EAM, Tomio C, Moreno YMF, Daltoe FP, Barbosa E, et al. Altered intestinal microbiota composition, antibiotic therapy and intestinal inflammation in children and adolescents with cystic fibrosis. PLoS One. 2018;13(6):e0198457.","DOI":"10.1371\/journal.pone.0198457"},{"issue":"1","key":"10.1016\/j.prrv.2020.12.001_b0375","doi-asserted-by":"crossref","DOI":"10.1038\/srep24857","article-title":"Disrupted progression of the intestinal microbiota with age in children with cystic fibrosis","volume":"6","author":"Nielsen","year":"2016","journal-title":"Sci Rep"},{"issue":"4","key":"10.1016\/j.prrv.2020.12.001_b0380","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1016\/j.jcf.2020.04.007","article-title":"Development of the gut microbiota in early life: The impact of cystic fibrosis and antibiotic treatment","volume":"19","author":"Kristensen","year":"2020","journal-title":"J Cyst Fibros"},{"issue":"7","key":"10.1016\/j.prrv.2020.12.001_b0385","doi-asserted-by":"crossref","first-page":"1661","DOI":"10.1002\/ppul.24766","article-title":"Age and environmental exposures influence the fecal bacteriome of young children with cystic fibrosis","volume":"55","author":"Loman","year":"2020","journal-title":"Pediatr Pulmonol"},{"key":"10.1016\/j.prrv.2020.12.001_b0390","doi-asserted-by":"crossref","unstructured":"Meeker SM, Mears KS, Sangwan N, Brittnacher MJ, Weiss EJ, Treuting PM, et al. CFTR dysregulation drives active selection of the gut microbiome. PLoS Pathog. 2020;16(1):e1008251.","DOI":"10.1371\/journal.ppat.1008251"},{"key":"10.1016\/j.prrv.2020.12.001_b0395","doi-asserted-by":"crossref","unstructured":"Vernocchi P, Del Chierico F, Russo A, Majo F, Rossitto M, Valerio M, et al. Gut microbiota signatures in cystic fibrosis: Loss of host CFTR function drives the microbiota enterophenotype. PLoS One. 2018;13(12):e0208171.","DOI":"10.1371\/journal.pone.0208171"},{"key":"10.1016\/j.prrv.2020.12.001_b0400","doi-asserted-by":"crossref","unstructured":"Li L, Somerset S. Associations between flavonoid intakes and gut microbiota in a group of adults with cystic fibrosis. Nutrients. 2018;10(9).","DOI":"10.3390\/nu10091264"},{"issue":"1","key":"10.1016\/j.prrv.2020.12.001_b0405","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1186\/s12866-017-0968-8","article-title":"The altered gut microbiota in adults with cystic fibrosis","volume":"17","author":"Burke","year":"2017","journal-title":"BMC Microbiol"},{"issue":"2","key":"10.1016\/j.prrv.2020.12.001_b0410","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1097\/MPG.0000000000002197","article-title":"Decreased fecal calprotectin levels in cystic fibrosis patients after antibiotic treatment for respiratory exacerbation","volume":"68","author":"Schnapp","year":"2019","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"10.1016\/j.prrv.2020.12.001_b0415","doi-asserted-by":"crossref","unstructured":"Coffey MJ, Low I, Stelzer-Braid S, Wemheuer B, Garg M, Thomas T, et al. The intestinal virome in children with cystic fibrosis differs from healthy controls. PLoS One. 2020;15(5):e0233557.","DOI":"10.1371\/journal.pone.0233557"},{"issue":"2","key":"10.1016\/j.prrv.2020.12.001_b0420","doi-asserted-by":"crossref","DOI":"10.1093\/femsec\/fiw230","article-title":"Impact of cystic fibrosis disease on archaea and bacteria composition of gut microbiota","volume":"93","author":"Miragoli","year":"2017","journal-title":"FEMS Microbiol Ecol"},{"issue":"3","key":"10.1016\/j.prrv.2020.12.001_b0425","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1097\/MPG.0000000000002185","article-title":"Systematic review of probiotics for cystic fibrosis patients: moving forward","volume":"68","author":"Neri","year":"2019","journal-title":"J Pediatr Gastroenterol Nutr"},{"issue":"4","key":"10.1016\/j.prrv.2020.12.001_b0430","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1007\/s12519-017-0033-6","article-title":"Does probiotic supplementation affect pulmonary exacerbation and intestinal inflammation in cystic fibrosis: a systematic review of randomized clinical trials","volume":"13","author":"Nikniaz","year":"2017","journal-title":"World J Pediatr"},{"key":"10.1016\/j.prrv.2020.12.001_b0435","doi-asserted-by":"crossref","unstructured":"Kanhere M, He J, Chassaing B, Ziegler TR, Alvarez JA, Ivie EA, et al. Bolus Weekly Vitamin D3 Supplementation Impacts Gut and Airway Microbiota in Adults With Cystic Fibrosis: A Double-Blind, Randomized, Placebo-Controlled Clinical Trial. J Clin Endocrinol Metab. 2018;103(2):564-74.","DOI":"10.1210\/jc.2017-01983"},{"key":"10.1016\/j.prrv.2020.12.001_b0440","doi-asserted-by":"crossref","unstructured":"Vernocchi P, Del Chierico F, Quagliariello A, Ercolini D, Lucidi V, Putignani L. A Metagenomic and in silico functional prediction of gut microbiota profiles may concur in discovering new cystic fibrosis patient-targeted probiotics. Nutrients. 2017;9(12).","DOI":"10.3390\/nu9121342"},{"issue":"1","key":"10.1016\/j.prrv.2020.12.001_b0445","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-018-36364-6","article-title":"Impact of CFTR modulation with Ivacaftor on Gut Microbiota and Intestinal Inflammation","volume":"8","author":"Ooi","year":"2018","journal-title":"Sci Rep"},{"issue":"2","key":"10.1016\/j.prrv.2020.12.001_b0450","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1513\/AnnalsATS.201510-669LE","article-title":"Resolution of intestinal histopathology changes in cystic fibrosis after treatment with ivacaftor","volume":"13","author":"Safe","year":"2016","journal-title":"Ann Am Thorac Soc"},{"key":"10.1016\/j.prrv.2020.12.001_b0455","doi-asserted-by":"crossref","DOI":"10.1016\/j.jpeds.2018.05.018","article-title":"Energy balance and mechanisms of weight gain with ivacaftor treatment of cystic fibrosis gating mutations","volume":"201","author":"Stallings","year":"2018","journal-title":"J Pediatr"},{"issue":"6","key":"10.1016\/j.prrv.2020.12.001_b0460","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1016\/S1470-2045(18)30188-8","article-title":"Risk of gastrointestinal cancers in patients with cystic fibrosis: a systematic review and meta-analysis","volume":"19","author":"Yamada","year":"2018","journal-title":"Lancet Oncol"},{"issue":"8","key":"10.1016\/j.prrv.2020.12.001_b0465","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1056\/NEJM199502233320803","article-title":"The risk of cancer among patients with cystic fibrosis","volume":"332","author":"Neglia","year":"1995","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.prrv.2020.12.001_b0470","doi-asserted-by":"crossref","first-page":"282","DOI":"10.4251\/wjgo.v8.i3.282","article-title":"Emerging role of cystic fibrosis transmembrane conductance regulator - an epithelial chloride channel in gastrointestinal cancers","volume":"8","author":"Hou","year":"2016","journal-title":"World J Gastrointest Oncol"},{"issue":"1","key":"10.1016\/j.prrv.2020.12.001_b0475","doi-asserted-by":"crossref","DOI":"10.1186\/s13073-020-0710-2","article-title":"Interactions between the gut microbiome and host gene regulation in cystic fibrosis","volume":"12","author":"Dayama","year":"2020","journal-title":"Genome Med"},{"issue":"3","key":"10.1016\/j.prrv.2020.12.001_b0480","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1053\/j.gastro.2017.12.012","article-title":"Cystic fibrosis colorectal cancer screening consensus recommendations","volume":"154","author":"Hadjiliadis","year":"2018","journal-title":"Gastroenterology"},{"issue":"3","key":"10.1016\/j.prrv.2020.12.001_b0485","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1053\/j.gastro.2017.10.036","article-title":"Cost effectiveness of screening individuals with cystic fibrosis for colorectal cancer","volume":"154","author":"Gini","year":"2018","journal-title":"Gastroenterology"},{"issue":"6","key":"10.1016\/j.prrv.2020.12.001_b0490","first-page":"1484","article-title":"Ursodeoxycholic acid for liver disease associated with cystic fibrosis: a double-blind multicenter trial","volume":"23","author":"Colombo","year":"1996","journal-title":"Hepatology"},{"issue":"1","key":"10.1016\/j.prrv.2020.12.001_b0495","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/S0022-3476(97)70310-X","article-title":"Ursodeoxycholic acid improves the hepatic metabolism of essential fatty acids and retinol in children with cystic fibrosis","volume":"130","author":"Lepage","year":"1997","journal-title":"J Pediatr"},{"issue":"2","key":"10.1016\/j.prrv.2020.12.001_b0500","first-page":"198","article-title":"Effect of a medium dose of ursodeoxycholic acid with or without taurine supplementation on the nutritional status of patients with cystic fibrosis: a randomized, placebo-controlled, crossover trial","volume":"19","author":"Merli","year":"1994","journal-title":"J Pediatr Gastroenterol Nutr"},{"issue":"5","key":"10.1016\/j.prrv.2020.12.001_b0505","first-page":"477","article-title":"Serum bile acids and ursodeoxycholic acid treatment in cystic fibrosis-related liver disease","volume":"8","author":"O'Brien","year":"1996","journal-title":"Eur J Gastroenterol Hepatol"}],"container-title":["Paediatric Respiratory Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1526054220301810?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1526054220301810?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T19:36:38Z","timestamp":1761507398000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1526054220301810"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6]]},"references-count":101,"alternative-id":["S1526054220301810"],"URL":"https:\/\/doi.org\/10.1016\/j.prrv.2020.12.001","relation":{},"ISSN":["1526-0542"],"issn-type":[{"value":"1526-0542","type":"print"}],"subject":[],"published":{"date-parts":[[2022,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Changing paradigms in the treatment of gastrointestinal complications of cystic fibrosis in the era of cystic fibrosis transmembrane conductance regulator modulators","name":"articletitle","label":"Article Title"},{"value":"Paediatric Respiratory Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.prrv.2020.12.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}